AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28917618 — intervention group
Group type: COMPARATOR
Intervention: Measured Resection
Number of subjects: 103
Study 27742627 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified STarT Back Tool score
Number of subjects: 2969
Study 24886786 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Shift SBIRT intervention
Number of subjects: 700
Study 24886786 — intervention group
Group type: COMPARATOR
Intervention: Shift Gears attention-placebo control
Number of subjects: 700
Study 23525432 — intervention group
Group type: EXPERIMENTAL
Intervention: urocortin 2 (3.6 to 120 pmol/min)
Number of subjects: 18
Study 23525432 — intervention group
Group type: EXPERIMENTAL
Intervention: urocortin 3 (1.2 to 36 nmol/min)
Number of subjects: 18
Study 23525432 — intervention group
Group type: EXPERIMENTAL
Intervention: substance P (2 to 8 pmol/min)
Number of subjects: 18
Study 23525432 — intervention group
Group type: EXPERIMENTAL
Intervention: urocortin 2 and urocortin 3 in the presence of all 3 inhibitors (aspirin, fluconazole, L‐NMMA)
Number of subjects: 18
Study 20870121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-saving photorefractive keratectomy (PRK) using Zyoptix algorithm
Number of subjects: 93
Study 20870121 — intervention group
Group type: COMPARATOR
Intervention: Conventional photorefractive keratectomy (PRK) using PlanoScan algorithm
Number of subjects: 93
Study 19064853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy aimed at near-normal glycemia
Number of subjects: 1211
Study 19064853 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1211
Study 16608158 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong therapeutic alliance
Number of subjects: 785
Study 16608158 — intervention group
Group type: COMPARATOR
Intervention: Low therapeutic alliance
Number of subjects: 785
Study 16608158 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy
Number of subjects: 785
Study 16608158 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance (general)
Number of subjects: 785
Study 12918543 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study 12918543 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 0
Study 12145792 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination endoscopic therapy (with epinephrine injection, shaving down the clot with cold guillotining, and bipolar coagulation on the underlying stigmata)
Number of subjects: 32
Study 12145792 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 32
Study 9651664 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (beta 1‐ and beta 2‐adrenoceptor partial agonist)
Number of subjects: 12
Study 9651664 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (beta 1‐ and beta 2‐adrenoceptor antagonist)
Number of subjects: 12
Study 9651664 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (beta 1‐adrenoceptor antagonist)
Number of subjects: 12
Study 9651664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7980716 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 meals/day
Number of subjects: 16
Study 7980716 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 meals/day
Number of subjects: 16
Study 2646846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg p.o. + 200 mg i.m.)
Number of subjects: 21
Study 2646846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg p.o. + 50 mg i.m.)
Number of subjects: 21
Study 2646846 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 31909412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Africa intervention delivered by community health workers (CHWs) through video-assisted sessions and supplemented with text messages
Number of subjects: 200
Study 31909412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Africa intervention
Number of subjects: 200
Study 31053989 — intervention group
Group type: EXPERIMENTAL
Intervention: Orantinib
Number of subjects: 432
Study 31053989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 31053989 — intervention group
Group type: EXPERIMENTAL
Intervention: Orantinib (BCLC-B subgroup)
Number of subjects: 432
Study 31053989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BCLC-B subgroup)
Number of subjects: 432
Study 28525821 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and exercise
Number of subjects: 54
Study 28525821 — intervention group
Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 54
Study 26415812 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenxin Keli
Number of subjects: 1200
Study 26415812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 23900661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 years of lead time in full health preceding 5 years of unhealthy time (standard)
Number of subjects: 2
Study 23900661 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of lead time preceding 5 years of unhealthy time (experimental)
Number of subjects: 2
Study 23900661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 years of lead time and 5 years of unhealthy time, presented with a visual aid (experimental)
Number of subjects: 2
Study 21312188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electrical stimulation (PES)
Number of subjects: 70
Study 21312188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19815286 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video, review of barriers, regular phone call reminders, audible and visible reminders on DA devices
Number of subjects: 66
Study 19815286 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions to take drops as prescribed with no additional intervention
Number of subjects: 66
Study 16711274 — intervention group
Group type: EXPERIMENTAL
Intervention: AR splint (Group I)
Number of subjects: 50
Study 16711274 — intervention group
Group type: EXPERIMENTAL
Intervention: SVED and MORA splints (Group II)
Number of subjects: 50
Study 16711274 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 50
Study 15002083 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 500 mg twice daily for 2 weeks
Number of subjects: 0
Study 11708573 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day for 8 weeks
Number of subjects: 56
Study 11708573 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day for the next 8 weeks
Number of subjects: 56
Study 11708573 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 56
Study 11708573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9144826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for preventing aggression including a protocol for talking to patients, discussing treatment goals, explaining locked door policies, providing staff meeting schedules, and clarifying appointment procedures.
Number of subjects: 0
Study 9144826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for preventing aggression
Number of subjects: 0
Study 9144826 — intervention group
Group type: COMPARATOR
Intervention: Control wards (no specific interventions implemented)
Number of subjects: 0
Study 8198303 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 (added an abdominal strap to the control technique)
Number of subjects: 19
Study 8198303 — intervention group
Group type: COMPARATOR
Intervention: Control technique (standard strapping without abdominal strap)
Number of subjects: 19
Study 3309074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg) administered 30 min before amphotericin B
Number of subjects: 0
Study 3309074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30663869 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg baricitinib
Number of subjects: 3492
Study 30663869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3492
Study 30663869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg baricitinib
Number of subjects: 3492
Study 30663869 — intervention group
Group type: EXPERIMENTAL
Intervention: All-bari-RA (all doses)
Number of subjects: 3492
Study 27846612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose plerixafor (480 μg/kg)
Number of subjects: 23
Study 27846612 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose plerixafor (240 μg/kg)
Number of subjects: 23
Study 25272318 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP plus 2 ranibizumab injections
Number of subjects: 30
Study 25272318 — intervention group
Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 30
Study 23672633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 62
Study 23672633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21446219 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 20
Study 21446219 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-oxidant treatment (vitamin C-100 mg BD and vitamin E-400 IU BD) for 45 days
Number of subjects: 20
Study 21446219 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy normal subjects)
Number of subjects: 20
Study 18997671 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted weight loss program
Number of subjects: 213
Study 18997671 — intervention group
Group type: COMPARATOR
Intervention: General health control group
Number of subjects: 213
Study 16786406 — intervention group
Group type: EXPERIMENTAL
Intervention: Gruesome photographs
Number of subjects: 0
Study 16786406 — intervention group
Group type: COMPARATOR
Intervention: No photographs (neutral evidence)
Number of subjects: 0
Study 15373936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumarate tablet (120 mg dimethylfumarate and 95 mg calcium‐monoethylfumarate) taken in the fasted state
Number of subjects: 10
Study 15373936 — intervention group
Group type: COMPARATOR
Intervention: Fumarate tablet taken after a standardized breakfast
Number of subjects: 10
Study 11419825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg every day or 325 mg every 3 days)
Number of subjects: 61
Study 11419825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 61
Study 11419825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9173339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen-progestin contraception
Number of subjects: 45
Study 9173339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 45
Study 8282457 — intervention group
Group type: EXPERIMENTAL
Intervention: More than six sexual partners
Number of subjects: 257
Study 8282457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives for > 10 years
Number of subjects: 257
Study 2881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 30
Study 2881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 30
Study 2881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study 31895298 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lactalbumin (LA)
Number of subjects: 11
Study 31895298 — intervention group
Group type: COMPARATOR
Intervention: Collagen peptides (CP)
Number of subjects: 11
Study 30375497 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterisation of dissolved organic matter (DOM) using a novel liquid chromatography ‐mass spectrometry method
Number of subjects: 74
Study 30375497 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DOM composition with groundwater flow‐paths and regional mean temperature
Number of subjects: 74
Study 30375497 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the impact of groundwater geochemistry and climate on DOM composition
Number of subjects: 74
Study 26545392 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training combined with compelled weight-shift therapy (experimental group, n=14)
Number of subjects: 28
Study 26545392 — intervention group
Group type: COMPARATOR
Intervention: Gait training alone (control group, n=14)
Number of subjects: 28
Study 26106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural motor adaptation in PwMS
Number of subjects: 0
Study 26106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity in PwMS
Number of subjects: 0
Study 26106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortico-cerebellar connectivity in PwMS
Number of subjects: 0
Study 26106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortico-striatal connectivity in PwMS
Number of subjects: 0
Study 23114833 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (used before and during endurance exercise)
Number of subjects: 2
Study 23114833 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no Acipimox)
Number of subjects: 2
Study 20456839 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine treatment plus Western medicine (group A)
Number of subjects: 537
Study 20456839 — intervention group
Group type: COMPARATOR
Intervention: Western medicine plus placebo (group B)
Number of subjects: 537
Study 17360151 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity (EPA) intervention
Number of subjects: 29
Study 17360151 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 29
Study 14744743 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw cabbage
Number of subjects: 12
Study 14744743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked cabbage
Number of subjects: 12
Study 14744743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard
Number of subjects: 12
Study 11846968 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg (kg body mass)(‐1))
Number of subjects: 9
Study 11846968 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 9
Study 9569951 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF 100 ml/min
Number of subjects: 8
Study 7850539 — intervention group
Group type: EXPERIMENTAL
Intervention: IRP with melphalan followed by wide excision (WE) and fasciotomy
Number of subjects: 97
Study 7850539 — intervention group
Group type: COMPARATOR
Intervention: WE only
Number of subjects: 97
Study 3289929 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 150 mg I/ml
Number of subjects: 46
Study 3289929 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 200 mg I/ml
Number of subjects: 46
Study 29804486 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcuticular sutures using vicryl 3/0
Number of subjects: 169
Study 29804486 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted subcuticular suturing using vicryl 3/0
Number of subjects: 169
Study 29580594 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mL ice popsicle
Number of subjects: 208
Study 29580594 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of water at room temperature
Number of subjects: 208
Study 27099232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean seafood diet
Number of subjects: 20
Study 27099232 — intervention group
Group type: COMPARATOR
Intervention: Nonseafood diet
Number of subjects: 20
Study 25130571 — intervention group
Group type: EXPERIMENTAL
Intervention: HM-derived cream supplement
Number of subjects: 78
Study 25130571 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding regimen (control)
Number of subjects: 78
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Initial ZR
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita VM9
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram (censored for total fracture)
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram (total fracture with chipping)
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Initial ZR (total fracture with chipping)
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: VITA VM9 (total fracture with chipping)
Number of subjects: 90
Study 22196897 — intervention group
Group type: EXPERIMENTAL
Intervention: VITA VM9 (Weibull distributed data)
Number of subjects: 90
Study 19508549 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of the skin prior to incision with bupivacaine (Group A)
Number of subjects: 84
Study 19508549 — intervention group
Group type: COMPARATOR
Intervention: Half the bupivacaine infiltrated into the skin and the other half deep-to-external oblique (Group B)
Number of subjects: 84
Study 17971585 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted radiotherapy (P-RT)
Number of subjects: 451
Study 17971585 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiotherapy (SC-RT)
Number of subjects: 451
Study 17061753 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health fairs
Number of subjects: 236
Study 17061753 — intervention group
Group type: EXPERIMENTAL
Intervention: Private practice referrals
Number of subjects: 236
Study 17061753 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant referrals
Number of subjects: 236
Study 17061753 — intervention group
Group type: EXPERIMENTAL
Intervention: Community clinic referrals
Number of subjects: 236
Study 17061753 — intervention group
Group type: EXPERIMENTAL
Intervention: Community advertising and marketing
Number of subjects: 236
Study 17061753 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart review
Number of subjects: 236
Study 15015273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianzhi Granule (TZK) 0.5 g/bag, taken one bag three times a day for two courses of one month each
Number of subjects: 200
Study 15015273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianzhi Granule (TZK)
Number of subjects: 200
Study 11543498 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological monitoring during isolation in the HUBES experiment
Number of subjects: 9
Study 8739664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine, 15‐45 mg/day
Number of subjects: 115
Study 8739664 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline, 30‐90 mg/day
Number of subjects: 115
Study 1884876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine 72 mg daily for one month
Number of subjects: 21
Study 1884876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6760146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 214
Study 6760146 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 214
Study 30652528 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet plus supervised exercise training 3 hours per week (PD - EX)
Number of subjects: 22
Study 30652528 — intervention group
Group type: COMPARATOR
Intervention: Paleolithic diet and standard-care exercise recommendations (PD)
Number of subjects: 22
Study 28903733 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based curriculum (6 hours) covering communication skills, basics of genetic testing, risk assessment, ELSI issues, and practice behaviors.
Number of subjects: 121
Study 28903733 — intervention group
Group type: COMPARATOR
Intervention: Traditional Continuing Medical Education (CME) approach (clinical review articles).
Number of subjects: 121
Study 28903733 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based curriculum (6 hours).
Number of subjects: 121
Study 28903733 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Intervention and Control).
Number of subjects: 121
Study 24284692 — intervention group
Group type: COMPARATOR
Intervention: No glare
Number of subjects: 16
Study 24284692 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct glare
Number of subjects: 16
Study 24284692 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect glare
Number of subjects: 16
Study 24284692 — intervention group
Group type: EXPERIMENTAL
Intervention: Desk luminary glare
Number of subjects: 16
Study 24126295 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE study intervention
Number of subjects: 432
Study 24126295 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 432
Study 22540851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse radiofrequency treatment at 42°C for 120 seconds to the dorsal root ganglion
Number of subjects: 0
Study 22540851 — intervention group
Group type: COMPARATOR
Intervention: Low intensity test stimulation for 120 seconds
Number of subjects: 0
Study 19424808 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavioral intervention plus standardized cardiologic care (n = 39)
Number of subjects: 77
Study 19424808 — intervention group
Group type: COMPARATOR
Intervention: Standardized cardiologic care alone (n = 38)
Number of subjects: 77
Study 17304001 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball-specific balance training program
Number of subjects: 920
Study 17304001 — intervention group
Group type: COMPARATOR
Intervention: Standardized warm-up program
Number of subjects: 920
Study 14970281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad‐GM) to secrete GM‐CSF; Intradermal injections every 2 weeks for a total of three to six vaccinations
Number of subjects: 83
Study 11226653 — intervention group
Group type: EXPERIMENTAL
Intervention: Deantigenized dermal matrix with immediate thin autograft
Number of subjects: 17
Study 11226653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal matrix covered with bank allograft, autografted 1 week later
Number of subjects: 17
Study 11226653 — intervention group
Group type: COMPARATOR
Intervention: Thin donor sites used for dermal matrix coverage
Number of subjects: 17
Study 11226653 — intervention group
Group type: COMPARATOR
Intervention: Standard split thickness control graft
Number of subjects: 17
Study 10209702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg once daily)
Number of subjects: 632